Clinical Reviews in Bone and Mineral Metabolism

, Volume 5, Issue 1, pp 27–38

Treatment of renal osteodystrophy

  • Anca Gal-Moscovici
  • Stuart M. Sprague
  • Edgar V. Lerma


Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist’s concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy.

Key Words

renal osteodystrophy phosphate binders vitamin D receptor agonist cinacalcet parathyroidectomy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    US Renal Data system. 2004 USRDS 2004 Annual data report Bethesda, MD National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease.Google Scholar
  2. 2.
    Foley RN, Parfrey PS, Sarnak MJ. 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (5Suppl 3):S112–119.PubMedGoogle Scholar
  3. 3.
    Massry SG, Smogorzewski M. 1994 Mechanism to which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219–231.PubMedGoogle Scholar
  4. 4.
    Silver J, Kilav R, Naveh-Many T. 2002 Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283:F367–376.PubMedGoogle Scholar
  5. 5.
    Block JA, Hulbert-Shearon TE, Levin NW, Port FK. 1998 Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607–617.PubMedGoogle Scholar
  6. 6.
    Llach F, Yudd M. 1998 The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 13(Suppl 13):57–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Malluche HH, Monier-Faugere MC. 1999 Understanding and managing hyperphosphatemia in patients with chronic renal failure. Clin Nephrol 52:267–277.PubMedGoogle Scholar
  8. 8.
    Shigematsu T, Kazama JJ, Yamashita T et al. 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256.PubMedCrossRefGoogle Scholar
  9. 9.
    Inaba M, Nakatsuka K, Nagasue K et al. 2004 FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946.PubMedCrossRefGoogle Scholar
  10. 10.
    Fukuda N, Tanaka H, Tominaga Y et al. 1993 Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443.PubMedGoogle Scholar
  11. 11.
    Gogusev J, Duchambon P, Hory B et al. 1993 Depressed expression of calcium receptor in parathyroid gland Tissue of patients with hyperparathyroidism. Kidney Int 1993 Jan:51(1):328–336.CrossRefGoogle Scholar
  12. 12.
    Yano S, Sugimoto T, Tsukamoto T et al. 2000 Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58:1980–1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Kifor O, Moore FD Jr, Wang P et al. 1996 Reduced immunostaining for the extracellular Ca2+sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598–1606.PubMedCrossRefGoogle Scholar
  14. 14.
    Korkor AB. 1987 Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573–1577.PubMedCrossRefGoogle Scholar
  15. 15.
    Dusso AS. 2003 Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int (Suppl) Jun;(85):S6–9. Review.Google Scholar
  16. 16.
    Silver J. 2002 Pathogenesis of parathyroid dysfunction in end-stage renal disease Adv Ren Replace Ther 9: 159–167.PubMedCrossRefGoogle Scholar
  17. 17.
    Sherrard DJ, Hercz G, Pei Y et al. 1993 The spectrum of bone disease in chronic renal failure-an evolving disorder. Kidney Int 43:436–442.PubMedCrossRefGoogle Scholar
  18. 18.
    Malluche HH, Monier-Faugere MC. 1990 Renal bone disease 1990; an unmet challenge for the nephrologist. Kidney Int 38:193–211.PubMedCrossRefGoogle Scholar
  19. 19.
    Hruska KA, Teitelbaum SL. 1995 Renal osteodystrophy. N Engl J Med 333:166–174.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. 1995 The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of Vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419–1425.PubMedCrossRefGoogle Scholar
  21. 21.
    Quarles LD. 2005 Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int (Suppl) Jul;(96):S24–28. Review.Google Scholar
  22. 22.
    Dusso AS, Thadhani R, Slatopolsky E. 2004 Vitamin D receptor and analogs. Semin Nephrol 24:10–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Mizobuchi M, Hatamura I, Ogata H et al. 2004 Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15:2579–2587.PubMedCrossRefGoogle Scholar
  24. 24.
    Goldenberg MM. 1999 Paricalcitol, a new agent for the management of secondary hyperparathyroidism in pa-tients undergoing chronic renal dialysis. Clin Ther 21:432–441.PubMedCrossRefGoogle Scholar
  25. 25.
    Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. 1995 The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419–1425.PubMedCrossRefGoogle Scholar
  26. 26.
    Alfrey AC, LeGendre GR, Kaehny WD. 1976 The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294184–188.Google Scholar
  27. 27.
    Smith AJ, Faugere MC, Abreo K et al. 1986 Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6:275–283.PubMedGoogle Scholar
  28. 28.
    Faugere MC, Malluche HH. 1986 Stainable aluminum and not aluminum content reflects bone histology in dialysis patients. Kidney Int 30:717–722.PubMedCrossRefGoogle Scholar
  29. 29.
    Faugere MC, Malluche HH. 1996 Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11:111–120.Google Scholar
  30. 30.
    Malluche HH, Faugere MC. 1988 Aluminum related bone diseases. Blood Purif 6:1–15.PubMedGoogle Scholar
  31. 31.
    Goodman WG. 1985 Bone disease and aluminum: pathogenic considerations. Am J Kidney Dis 6:330–335.PubMedGoogle Scholar
  32. 32.
    Sedman AB, Alfrey AC, Miller NL, Goodman WG. 1987 Tissue and cellular basis for impaired bone formation in aluminum related osteomalacia in pig. J Clin Invest 79:86–92.PubMedGoogle Scholar
  33. 33.
    Quarles LD, Dennis VW, Gitelman GJ, Harrelson JM, Drezner MK. 1985 Aluminum deposition at the osteoid-bone interface. An epiphenomenon of the osteomalacic state in vitamin-D deficient dogs. J Clin Invest 75:1441–1447.PubMedGoogle Scholar
  34. 34.
    Goodman WG, Leite Duarte ME. 1991 Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolytes Metab 17:221–232.Google Scholar
  35. 35.
    Goodman WG, O’Connor J. 1991 Aluminum alters calcium influx and efflux from bone in vitro. Kidney Int 39:602–607.PubMedCrossRefGoogle Scholar
  36. 36.
    Malluche HH, Faugere MC, Smith AJ Jr, Friedler RM. 1986 Aluminum intoxication of bone in renal failure—fact or fiction? Kidney Int (Suppl) 18:S70–73.Google Scholar
  37. 37.
    D’Haese PC, Couttenye MM, De Broe ME. 1996 Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 1:74–79.Google Scholar
  38. 38.
    Diaz-Corte C, Fernandez-Martin LJ, Barreto S et al. 2001 Effect of aluminum load on parathyroid hormone synthesis. Nephrol Dial Transplant 16:742–745.PubMedCrossRefGoogle Scholar
  39. 39.
    Nordal KP. 1996 Calcium carbonate versus aluminum hydroxide as phosphate binder in hemodialysis patients. A randomized prospective study. Kidney Int 49:926.Google Scholar
  40. 40.
    Locatelli F, Cannata-Andia JB, Drueke TB et al. 2002 Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723–731.PubMedCrossRefGoogle Scholar
  41. 41.
    Martinez I, Saracho R, Montenegro J, Llach F. 1997 The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496–502.PubMedGoogle Scholar
  42. 42.
    Combe C, Aparicio M. 1994 Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381–1386.PubMedCrossRefGoogle Scholar
  43. 43.
    Hou SH, Zhao J, Ellman CF et al. 1991 Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217–224.PubMedGoogle Scholar
  44. 44.
    Achinger SG, Ayus JC. 2005 The role of daily dialysis in the control of hyperphosphatemia. Kidney Int (Suppl) Jun;(95):S28–32.Google Scholar
  45. 45.
    Emmett M, Sirmon MD, Kirkpatrick WG et al. 1991 Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 17:544–50.PubMedGoogle Scholar
  46. 46.
    Mai ML, Emmett M, Sheikh MS et al. 1989 Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690–695.PubMedCrossRefGoogle Scholar
  47. 47.
    Pflanz S, Henderson IS, McElduff N, Jones MC. 1994 Calcium acetate versus calcium carbonate as phosphatebinding agents in chronic haemodialysis. Nephrol Dial Transplant 9:1121–1124.PubMedGoogle Scholar
  48. 48.
    Schaefer K, Scheer J, Asmus G et al. 1991 The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 6:170–175.PubMedGoogle Scholar
  49. 49.
    National Kidney Foundation. 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic hemodialysis patients. J Am Kidney Dis 42(Suppl 3): S1–202.Google Scholar
  50. 50.
    Salusky IB, Foley J, Nelson P, Goodman WG. 1991 Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527–531.PubMedCrossRefGoogle Scholar
  51. 51.
    Hsu CH. 1997 Are we mismanaging calcium and phosphate in renal failure? Am J Kidney Dis 29:641–649.PubMedGoogle Scholar
  52. 52.
    Salusky IB, Ramirez JA, Oppenheim WL et al. 1994 Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253–258.PubMedCrossRefGoogle Scholar
  53. 53.
    Llach F, Fensenfeld AJ, Coleman MD, Pederson JA. Prevalence of various types of bone disease in dialysis patients. Nephrology, Proceedings of the ninth International Congress of Nephrology, vol II, edited by Robinson RR, New-York, Springer Verlag, 1984, 1375–1382.Google Scholar
  54. 54.
    Kurz P, Mauniere-Faugere MC, Bognar B et al. 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855–861.PubMedCrossRefGoogle Scholar
  55. 55.
    London MG, Marty C, Marchais SJ et al. 2004 Arterial calcification and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943–1951.PubMedCrossRefGoogle Scholar
  56. 56.
    Guerin AP, London GM, Marchais SJ, Metivier F. 2000 Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014–1021.PubMedCrossRefGoogle Scholar
  57. 57.
    Fournier A, Moriniere P, Cohen-Solal ME et al. 1991 Adynamic bone disease in uremia: may it be idiopathic? Is it an actual disease? Nephron 58:1–12.PubMedGoogle Scholar
  58. 58.
    Frost HF. 1963 Measurement of human bone formation by means of tetracycline labeling. Can J Biochem Biophys 41:31–38.Google Scholar
  59. 59.
    Coco M, Rush H. 2000 Increase incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121.PubMedGoogle Scholar
  60. 60.
    Mittalhenkle A, Gillen DL, Stehman-Breen CO. 2004 Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44:672–679.PubMedCrossRefGoogle Scholar
  61. 61.
    Wilkes BM, Reiner D, Kern M et al. 1998 Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenGel) in dialysis patients. Clin Nephrol 50:381–386.PubMedGoogle Scholar
  62. 62.
    Bleyer AJ, Burke SK, Dillon M et al. 1999 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694–701.PubMedGoogle Scholar
  63. 63.
    Hervas JG, Prados D, Cerezo S. 2003 Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int Suppl Jun;(85):S69–72.Google Scholar
  64. 64.
    Qunibi WY, Hootkins RE, McDowell LL et al. 2004 Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (CARE study). Kidney Int 65:1914–1926.PubMedCrossRefGoogle Scholar
  65. 65.
    Chertow GM, Burke SK, Raggi P. 2002 Treat to goal working group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252.PubMedCrossRefGoogle Scholar
  66. 66.
    Behets GJ, Gritters M, Dams G, De Broe ME, D’Haese PC. 2005 Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 27:475–84.PubMedGoogle Scholar
  67. 67.
    Drug Topic 2003 Redbook, Monvale, NJ, Thomson PDR, 2003.Google Scholar
  68. 68.
    Behets GJ, Verberckmoes SC, D’Haese PC, De Broe ME. 2004 Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 13:403–409. Review.PubMedCrossRefGoogle Scholar
  69. 69.
    Lacour B, Lucas A, Auchere D et al. 2005 Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005 Mar;67(3):1062–1069.CrossRefGoogle Scholar
  70. 70.
    Slatopolsky E, Liapis H, Finch J. 2005 Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68:2809–2813.PubMedCrossRefGoogle Scholar
  71. 71.
    Bervoets AR, Oste L, Behets GJ et al. 2006 Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone Jan 10; (E pub ahead of print).Google Scholar
  72. 72.
    Damment SJ, Shen V. 2005 Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 63:127–137.PubMedGoogle Scholar
  73. 73.
    Hutchinson AJ. 1999 Calcitriol, lanthanum carbonate and other phosphate binders in the management of renal osteodystrophy. Perit Dial Int 19(Suppl 2):408–412.Google Scholar
  74. 74.
    Finn WF, Joy MS, Hladik G, Lanthanum Study Group. 2004 Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 62:193–201.PubMedGoogle Scholar
  75. 75.
    Joy MS, Finn WF, LAM-302 Study Group. 2003 Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96–107.PubMedCrossRefGoogle Scholar
  76. 76.
    D’Haese PC, Spasowski GB, Sikole A et al. 2003 A multicenter study on the effect of lanthanum carbonate (Forsenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63(Suppl 65):S73–78.CrossRefGoogle Scholar
  77. 77.
    Hergesell O, Ritz E. 1999 Phosphate binders on iron bases: a new perspective. Kidney Int 56(Suppl 73):42–45.CrossRefGoogle Scholar
  78. 78.
    Holick MF. 2005 Vitamin D for health and in chronic kidney disease. Semin Dial 18:266–275.PubMedCrossRefGoogle Scholar
  79. 79.
    Zanello SB, Collins ED, Marinissen MJ, Norman AW, Boland RL. 1997 Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm Metab Res 29:231–236.PubMedCrossRefGoogle Scholar
  80. 80.
    Tovar Sepulveda VA, Weigel NL, Falzon M. 2006 Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 71:102–115 (E pub 2005 Oct 21).CrossRefGoogle Scholar
  81. 81.
    Albrechtsson E, Jonsson T, Moller S et al. 2003 Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology 2003;3(1):41–46.PubMedCrossRefGoogle Scholar
  82. 82.
    Chang TJ, Lei HH, Yeh JI et al. 2000 Vitamin D receptor gene polymorphisms influence susceptibility to type1 diabetes mellitus in the Taiwanese population. Clin Endocrinol (Oxf) 52:575–80.CrossRefGoogle Scholar
  83. 83.
    McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles DW. 2004 Vitamin D3-implications for brain development. J Steroid Biochem Mol Biol 89–90:557–560. Review.PubMedCrossRefGoogle Scholar
  84. 84.
    Nguyen TM, Pavlovitch J, Papiernik M et al. 1997 Changes in 1,25-(OH)2D3 synthesis and its receptor expression in spleen cell subpopulations of mice infected with LPBM5 retrovirus. Endocrinology 138:5505–5510.PubMedCrossRefGoogle Scholar
  85. 85.
    Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF. 1981 Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 15:18–22.PubMedGoogle Scholar
  86. 86.
    Fratzl-Zelman N, Glantschnig H, Rumpler M et al. 2003 The expression of matrix metalloproteinase-13 and osteocalcin in mouse osteoblasts is related to osteoblastic differentiation and is modulated by 1,25-dihydroxyvitamin D3 and thyroid hormones. Cell Biol Int 27 459–468.PubMedCrossRefGoogle Scholar
  87. 87.
    Staal A, Geertsma-Kleinekoort WM, Van Den Bemd GJ et al. 1998 Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I. J Bone Miner Res 13:36–43.PubMedCrossRefGoogle Scholar
  88. 88.
    Gram J, Junker P, Nielsen HK, Bollerslev J. 1996 Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males. Bone 18:539–544.PubMedCrossRefGoogle Scholar
  89. 89.
    Bro S, Olgaard K. 1997 Effects of excess PTH on non-classical target organs. Am J Kidney Dis 30:606–620.PubMedGoogle Scholar
  90. 90.
    Silver J, Russell J, Sherwood LM. 1985 Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 82:4270–4273.PubMedCrossRefGoogle Scholar
  91. 91.
    Salusky IB, Goodman WG. 2001 Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985. Review.PubMedGoogle Scholar
  92. 92.
    Salusky IB, Kuizon BD, Belin TR et al. 1998 Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907–914.PubMedCrossRefGoogle Scholar
  93. 93.
    Goodman WG, Ramirez JA, Belin TR. 1994 Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166.PubMedCrossRefGoogle Scholar
  94. 94.
    Goodman WG, Salusky IB. 1991 Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol 90:189–195.PubMedGoogle Scholar
  95. 95.
    Takahashi F, Finch JL, Denda M et al. 1997 A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-.PubMedGoogle Scholar
  96. 96.
    Slatopolsky E, Finch J, Ritter C et al. 1995 A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852–860.PubMedGoogle Scholar
  97. 97.
    Staniforth ME, Cheng SC, Coyne DW. 2005 Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol 63:454–460.PubMedGoogle Scholar
  98. 98.
    Coyne DW, Grieff M, Ahya SN et al. 2002 Differential effects of acute administration of 19-Nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283–1288.PubMedCrossRefGoogle Scholar
  99. 99.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. 2003 Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63:1483–1490.PubMedCrossRefGoogle Scholar
  100. 100.
    Teng M, Wolf M, Lowrie E et al. 2003 Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456.PubMedCrossRefGoogle Scholar
  101. 101.
    Dobrez DG, Mathes A, Amdahl M et al. 2004 Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174–1181.PubMedCrossRefGoogle Scholar
  102. 102.
    Torres PU. Clinical experience with cinacalcet HCl. 2004 Nephrol Dial Transplant 19(Suppl 5):27–33.CrossRefGoogle Scholar
  103. 103.
    Block GA, Martin KJ, de Francisco AL et al. 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525.PubMedCrossRefGoogle Scholar
  104. 104.
    Vadam M, Nagano N, Furuya Y et al. 2000 Calcimimetic NPS R-568 prevent parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50–58.CrossRefGoogle Scholar
  105. 105.
    Vadam M, Furuya Y, Sakiyama J et al. 1997 The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via calcium receptor. J Clin Invest 100:2977–2983.CrossRefGoogle Scholar
  106. 106.
    Vadam M, Furuya Y, Sakiyama J et al. 1997 NPS R-568 halts or reverses osteoitis fibrosis in uremic rats. Kidney Int 53:448–453.Google Scholar
  107. 107.
    Goodman WG, Fravo GM, Goodkin DA et al. 2000 A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445.PubMedCrossRefGoogle Scholar
  108. 108.
    Lindberg JS, Moe SM, Goodman WG et al. 2003 Calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphate in secondary hyperparathyroidism. Kidney Int 63:248–254.PubMedCrossRefGoogle Scholar
  109. 109.
    Drueke TB, Cunningham J, Goodman WG et al. 2001 Short term treatment of secondary hyperparathyroidism (SHPT) with calcimimetic agent AMG073. Am J Soc Nephrol 12:764A.Google Scholar
  110. 110.
    De Francisco ALM, Surany M, Cunningham J et al. 2003 Oral cinacalcet HCl (AMG073) for the treatment of hemodialysis patients with secondary hyperparathyroidism, results of an European/Australian phase 3 study. J Am Soc Nephrol 14:461A.Google Scholar
  111. 111.
    Brach GA, Martin KJ, De Francisco ALM et al. 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1520–1529.Google Scholar
  112. 112.
    Lindberg JS, Culleton B, Wong G et al. 2003 Phase 3 experience with cinacalcet HCl and hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 14:36A.Google Scholar
  113. 113.
    Moe SM, Cunningham J, Bommer J et al. 2005 Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186–2193.PubMedCrossRefGoogle Scholar
  114. 114.
    Yasunaga C, Nakamoto M, Matsuo K, et al. Effects of parathroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999; 178: 332.PubMedCrossRefGoogle Scholar
  115. 115.
    Garcia-Clanton C, Palomar R, Moreno A, et al. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism. Nephron 1996; 74: 444.Google Scholar
  116. 116.
    Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: The role of “suppressed” parathyroid function. Kidney Int 1993; 44: 860.PubMedCrossRefGoogle Scholar
  117. 117.
    Gagne ER, Urena P, Silva SL, et al. Short and long-term efficacy of total parathyroidectomy with immediate ato-grafting compared with sub-total parathyroidectomy. in hemodialysis patients. J Am Soc Nephrol 1992; 3:1008.PubMedGoogle Scholar
  118. 118.
    Agus Z, Berkoben M, Quarles LD. Hungry bone syndrome following parathyroidectomy. UptoDate 2007.Google Scholar
  119. 119.
    Kitaoka M, Onoda N, Kitamura H, et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003; 18 Suppl 3: III38.Google Scholar
  120. 120.
    Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single center study. Nephrol Dial Transplant 2005; 20:1714.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2007

Authors and Affiliations

  • Anca Gal-Moscovici
    • 1
    • 2
  • Stuart M. Sprague
    • 2
  • Edgar V. Lerma
    • 3
  1. 1.Hadassah Hospital Medical CenterHebrew UniversityEin Keren, JeruslaemIsrael
  2. 2.Division of Nephrology and Hypertension, Evanston Northwestern HealthcareNorthwestern University Feinberg School of MedicineEvanston
  3. 3.Section of NephrologyUniversity of Illinois at Chicago College of Medicine/Associates in NephrologyChicago
  4. 4.Evanston

Personalised recommendations